Cancer Trials Ireland > Cancer Trials > Lymphoma & blood cancers > Lymphoma

DSSG Group: Lymphoma

Beigene 311-308 / MAHOGANY

Name No. For Patients with Purpose
Beigene 311-308 / MAHOGANY 24-30

Relapsed/Refractory Follicular or Marginal Zone Lymphoma
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Cell-free DNA

Name No. For Patients with Purpose
Cell-free DNA 24-29

High Grade non-Hodgkin’s lymphoma

firmMIND INCMOR0208-305

Name No. For Patients with Purpose
firmMIND INCMOR0208-305 24-05

Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).